论文部分内容阅读
目的评价化疗联用微卡菌苗治疗初治菌阳肺结核的疗效。方法将96例初治菌阳肺结核患者随机分成A、B组,A组(50)例采用2HERZ／4HR加微卡菌苗方案治疗,B组(46例)单纯用2HERZ／4HR方案治疗,观察治疗后肺部病灶吸收和痰菌阴转情况。结果第2个月末痰菌阴转率A、B组分别为96．0％和78．3％;疗程结束痰菌阴转率A、B组分别为98．0％和87．0％;疗程结束胸片改善有效率A、B组分别为96．0％和84．8％。结论微卡菌苗能提高初治菌阳肺结核患者痰菌阴转率,促进病灶吸收,是一种较好的免疫制剂。
Objective To evaluate the curative effect of chemotherapy combined with Mika vaccine on initial treatment of bacillary positive pulmonary tuberculosis. Methods 96 cases of newly diagnosed bacillary positive pulmonary tuberculosis patients were randomly divided into group A and group B. Group A (50 cases) were treated with 2HERZ / 4HR plus micro-bacilli vaccine. Group B (46 cases) were treated with 2HERZ / 4HR alone. Lung lesions after treatment absorption and sputum negative conversion situation. Results At the end of the second month, the sputum negative conversion rate was 96.0% in group A and 78.3% in group B, and the negative conversion rates of sputum in group A and B were 98.0% and 87.0% respectively at the end of treatment. The effectiveness of the end of the chest to improve efficiency A, B were 96.0% and 84.8%. Conclusions Mika vaccine can improve the sputum negative conversion rate and promote the absorption of the lesions in newly diagnosed bacillary positive pulmonary tuberculosis patients. It is a good immunological preparation.